Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma
Open Access
- 7 March 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 108 (6), 1260-1266
- https://doi.org/10.1038/bjc.2013.90
Abstract
Background: It is well known that renal cell carcinoma (RCC) represents one of the most immune-responsive cancers. Although the lack of defined antigens in RCC has hindered more specific vaccine development, research regarding vaccination therapy has been of special interest for the treatment of RCC for more than 30 years. Methods: To evaluate the safety of the vascular endothelial growth factor receptor 1 (VEGFR1) peptide vaccination and its clinical outcomes, data from 18 metastatic RCC (mRCC) patients treated with VEGFR1 vaccine were collected. Toxicity assessments were performed. Clinical outcomes included assessment using CT scanning, magnetic resonance imaging or X-ray examination in accordance with the WHO Response Evaluation Criteria in Solid Tumors. Results: No patient showed any toxicities of grade 3 or greater. Of the 18 patients, 2 patients showed a partial response during treatment. Stable disease for more than 5 months was observed in eight patients with a median duration of 16.5 months (4–32 months). At the time of the analysis in this study, six patients were alive with a median follow-up of 30 months (26–36 months). Conclusion: These results suggest that VEGFR1 peptide vaccine is safe and is recommended for further trials for patients with mRCC.Keywords
This publication has 30 references indexed in Scilit:
- Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigensJournal of Translational Medicine, 2012
- Phase I clinical trial of a novel peptide vaccine in combination with UFT/LV for metastatic colorectal cancerExperimental and Therapeutic Medicine, 2010
- Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancerCancer Science, 2010
- Phase I trial of personalized peptide vaccination for cytokine‐refractory metastatic renal cell carcinoma patientsCancer Science, 2007
- A Phase I Trial of Vaccination of CA9-Derived Peptides for HLA-A24-Positive Patients with Cytokine-Refractory Metastatic Renal Cell CarcinomaClinical Cancer Research, 2006
- Second-line strategies for metastatic renal cell carcinoma: classics and novel approachesZeitschrift für Krebsforschung und Klinische Onkologie, 2005
- Colorectal cancer vaccines: What we know and what we don’t yet knowSeminars in Oncology, 2005
- Natural selection of tumor variants in the generation of “tumor escape” phenotypesNature Immunology, 2002
- In Vitro Generation of Human Cytotoxic T Lymphocytes Specific for Peptides Derived From Prostate-Specific AntigenJNCI Journal of the National Cancer Institute, 1997
- Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.The Journal of Experimental Medicine, 1994